-
Je něco špatně v tomto záznamu ?
Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)
TA. Zwimpfer, E. Bilir, K. Gasimli, A. Cokan, N. Bizzarri, Z. Razumova, J. Kacperczyk-Bartnik, T. Nikolova, A. Pletnev, I. Kahramanoglu, A. Shushkevich, A. Strojna, C. Theofanakis, T. Cicakova, M. Vetter, C. Montavon, G. Morgan, V. Heinzelmann-Schwarz
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
20726
Swiss National Science Foundation - Switzerland
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
38539490
DOI
10.3390/cancers16061155
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1-2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3-4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.
2 Department of Obstetrics and Gynecology Medical University of Warsaw 02 091 Warsaw Poland
Cancer Center Cantonal Hospital Baselland Medical University Clinic 4410 Liestal Switzerland
Department of Biomedicine University of Basel 4031 Basel Switzerland
Department of Global Health Koç University Graduate School of Health Sciences 34010 Istanbul Turkey
Department of Gynecologic Oncology Ankara City Hospital 06680 Ankara Turkey
Department of Obstetrics and Gynecology University of Zielona Gora 65 729 Zielona Gora Poland
Department of Women's and Children's Health Karolinska Institutet 171 77 Stockholm Sweden
ESGO Office 110 00 Prague Czech Republic
Gynecological Cancer Center University Hospital Basel 4031 Basel Switzerland
Peter MacCallum Cancer Center East Melbourne VIC 3002 Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005588
- 003
- CZ-PrNML
- 005
- 20240412130941.0
- 007
- ta
- 008
- 240405s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers16061155 $2 doi
- 035 __
- $a (PubMed)38539490
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Zwimpfer, Tibor A $u Peter MacCallum Cancer Center, East Melbourne, VIC 3002, Australia $u Gynecological Cancer Center, University Hospital Basel, 4031 Basel, Switzerland $u Department of Biomedicine, University of Basel, 4031 Basel, Switzerland
- 245 10
- $a Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO) / $c TA. Zwimpfer, E. Bilir, K. Gasimli, A. Cokan, N. Bizzarri, Z. Razumova, J. Kacperczyk-Bartnik, T. Nikolova, A. Pletnev, I. Kahramanoglu, A. Shushkevich, A. Strojna, C. Theofanakis, T. Cicakova, M. Vetter, C. Montavon, G. Morgan, V. Heinzelmann-Schwarz
- 520 9_
- $a Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey, and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n = 103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Premedication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1-2 HSRs to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3-4 HSRs to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSRs in gynecologic cancer. Our study showed that HSRs in gynecologic cancer are common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSRs in gynecologic cancer was highlighted.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bilir, Esra $u Department of Global Health, Koç University Graduate School of Health Sciences, 34010 Istanbul, Turkey $u Department of Obstetrics and Gynecology, University Hospitals Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany $1 https://orcid.org/0000000344996543
- 700 1_
- $a Gasimli, Khayal $u Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Frankfurt Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany $1 https://orcid.org/0000000318740341
- 700 1_
- $a Cokan, Andrej $u Department for Gynaecological and Breast Oncology, University Medical Centre Maribor, 2000 Maribor, Slovenia $1 https://orcid.org/0000000251344466
- 700 1_
- $a Bizzarri, Nicolò $u UOC Ginecologia Oncologica, Dipartimento di Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy $1 https://orcid.org/000000021727904X
- 700 1_
- $a Razumova, Zoia $u Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden $1 https://orcid.org/0000000165980896
- 700 1_
- $a Kacperczyk-Bartnik, Joanna $u II Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-091 Warsaw, Poland $1 https://orcid.org/0000000325393894
- 700 1_
- $a Nikolova, Tanja $u Department of Obstetrics and Gynecology, Klinikum Mittelbaden, Academic Teaching Hospital of Heidelberg University, 76532 Baden-Baden, Germany
- 700 1_
- $a Pletnev, Andrei $u Department of Obstetrics and Gynecology, University of Zielona Gora, 65-729 Zielona Gora, Poland
- 700 1_
- $a Kahramanoglu, Ilker $u Department of Gynecologic Oncology, Ankara City Hospital, 06680 Ankara, Turkey
- 700 1_
- $a Shushkevich, Alexander $u Department of Obstetrics and Gynecology, Klinikum Friedrichshafen Medizin Campus Bodensee, 88048 Friedrichshafen, Germany $1 https://orcid.org/0000000297697240
- 700 1_
- $a Strojna, Aleksandra $u Department of Gynecology and Gynecologic Oncology, Evangelische Kliniken Essen Mitte, 45136 Essen, Germany $1 https://orcid.org/0000000287494642
- 700 1_
- $a Theofanakis, Charalampos $u Division of Gynaecologic Oncology, 1st Department of Obstetrics and Gynaecology, Alexandra Hospital, National and Kapodistrian University of Athens School of Health Sciences, 116 35 Athens, Greece $1 https://orcid.org/0000000239435971
- 700 1_
- $a Cicakova, Tereza $u ESGO Office, 110 00 Prague, Czech Republic
- 700 1_
- $a Vetter, Marcus $u Cancer Center, Cantonal Hospital Baselland, Medical University Clinic, 4410 Liestal, Switzerland $1 https://orcid.org/0009000410031078
- 700 1_
- $a Montavon, Céline $u Gynecological Cancer Center, University Hospital Basel, 4031 Basel, Switzerland $1 https://orcid.org/000000024186445X
- 700 1_
- $a Morgan, Gilberto $u The OncoAlert Network, 22185 Lund, Sweden $1 https://orcid.org/0000000260542384
- 700 1_
- $a Heinzelmann-Schwarz, Viola $u Gynecological Cancer Center, University Hospital Basel, 4031 Basel, Switzerland
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 6 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38539490 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130934 $b ABA008
- 999 __
- $a ok $b bmc $g 2075963 $s 1215350
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 16 $c 6 $e 20240314 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a 20726 $p Swiss National Science Foundation $2 Switzerland
- LZP __
- $a Pubmed-20240405
